{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:20:47Z","timestamp":1791073247586,"version":"4.1.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Effectiveness classification of disease-modifying therapies (DMTs) in MS relies either on head-to-head trials or indirect comparisons of annualized relapse rates (ARR) across studies. Validating efficacy estimates in real-world settings is crucial, particularly as the discussion on the broader use of high-efficacy (HE) DMTs including antibodies, S1P receptor modulators, and cladribine tablets, continues to evolve. Because treatment decisions in clinical practice are individualized and no single DMT is universally preferred, effectiveness assessments are appropriately conducted at the group level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the real-world effectiveness of HE vs. low-efficacy (LE) DMTs at the group level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective 1:1 propensity score-matched cohort study was conducted using routine data from MS patients initiating HE or LE DMTs at a German tertiary MS center between 2007 and 2023. Primary outcome was ARR; secondary endpoints were cumulative hazard of relapse, MRI activity, loss of NEDA-3, 3-month confirmed disability progression (CDP), and treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After matching, 266 datasets were analyzed with a median follow-up of 24 months in the LE DMT group and 43 months in the HE DMT group. ARR was 64% lower with HE DMTs (0.13 vs. 0.37; rate ratio 0.36, 95% \u2013CI: 0.23\u20130.53;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). Relapse hazard, MRI activity, and NEDA-3 loss were 53\u201363% lower (hazard ratios 0.41, 0.37, and 0.47; all\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). CDP did not differ between groups. Hazard of treatment discontinuation was 67\u201387% lower with HE DMTs (hazard ratios 0.13\u20130.33; all\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). No discontinuation due to recurrent infections occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HE DMTs resulted in significantly lower clinical and radiological disease activity than LE DMTs in real-world conditions while showing greater treatment persistence. These findings support the broad use of HE DMTs, while LE DMTs may be reserved for specific indications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1773074","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:25:32Z","timestamp":1773379532000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world effectiveness of high-efficacy therapies in multiple sclerosis: a propensity score-matched cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Jasmin","family":"Wich","sequence":"first","affiliation":[{"name":"Department of Neurology, Jena University Hospital","place":["Jena, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Beppler","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital","place":["Jena, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Dreiling","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jena University Hospital","place":["Jena, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Scherag","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital","place":["Jena, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jena University Hospital","place":["Jena, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rakers","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jena University Hospital","place":["Jena, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA."},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/nmt-2021-0058","article-title":"Updates and advances in multiple sclerosis neurotherapeutics","volume":"13","author":"Amin","year":"2023","journal-title":"Neurodegener Dis Manag."},{"key":"B3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2217\/cer-2020-0267","article-title":"Efficacy classification of modern therapies in multiple sclerosis","volume":"10","author":"Samjoo","year":"2021","journal-title":"J Comp Eff Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"New England Journal of Medicine."},{"key":"B5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","article-title":"Multiple sclerosis: time for early treatment with high-efficacy drugs","volume":"271","author":"Selmaj","year":"2024","journal-title":"J Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult Scler."},{"key":"B8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s42451-021-00334-6","article-title":"S2k-leitlinie: diagnose und therapie der multiplen sklerose, neuromyelitis-optica-spektrum-erkrankungen und mog-igg-assoziierten erkrankungen","volume":"4","author":"Berthele","year":"2021","journal-title":"DGNeurologie."},{"key":"B10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann Intern Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","article-title":"Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion","volume":"269","author":"Filippi","year":"2022","journal-title":"J Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing\u2013remitting multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s40265-023-01942-0","article-title":"Escalation versus induction\/high-efficacy treatment strategies for relapsing multiple sclerosis: which is best for patients?","volume":"83","author":"Edan","year":"2023","journal-title":"Drugs."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs. immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","article-title":"Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study","volume":"95","author":"Buron","year":"2020","journal-title":"Neurology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"11795735241260563","DOI":"10.1177\/11795735241260563","article-title":"Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: a propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments","volume":"16","author":"Muros-Le Rouzic","year":"2024","journal-title":"J Cent Nerv Syst Dis."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2024-ANZAN.120","article-title":"Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis","author":"Roos","year":"2024"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1212\/WNL.0000000000005772","article-title":"Fingolimod vs","volume":"91","author":"Prosperini","year":"2018"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1093\/brain\/awaa231","article-title":"Delay from treatment start to full effect of immunotherapies for multiple sclerosis","volume":"143","author":"Roos","year":"2020","journal-title":"Brain."},{"key":"B20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fneur.2022.875456","article-title":"Calculating and comparing the annualized relapse rate and estimating the confidence interval in relapsing neurological diseases","author":"Akaishi","year":"2022"},{"key":"B21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"The Lancet Neurology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1093\/brain\/awv258","article-title":"Defining reliable disability outcomes in multiple sclerosis","volume":"138","author":"Kalincik","year":"2015","journal-title":"Brain."},{"key":"B23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e000953","DOI":"10.1136\/rmdopen-2019-000953","article-title":"Three handy tips and a practical guide to improve your propensity score models","volume":"5","author":"Bergstra","year":"2019","journal-title":"RMD Open."},{"key":"B25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1177\/13524585221085733","article-title":"Recommendations for the use of propensity score methods in multiple sclerosis research","volume":"28","author":"Simoneau","year":"2022"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jclinepi.2013.06.001","article-title":"The z-difference can be used to measure covariate balance in matched propensity score analyses","volume":"66","author":"Kuss","year":"2013","journal-title":"J Clin Epidemiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-0-387-77318-6_4","article-title":"Regression models for count data in R","volume":"27","author":"Zeileis","year":"2008","journal-title":"J Stat Softw."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","article-title":"Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls","volume":"359","author":"Pocock","year":"2002","journal-title":"Lancet."},{"key":"B32","first-page":"1","article-title":"Using time dependent covariates and time dependent coefficients in the cox model","volume":"2","author":"Therneau","year":"2017","journal-title":"Survival Vignettes."},{"key":"B33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/rssb.12348","article-title":"Making sense of sensitivity: extending omitted variable bias","volume":"82","author":"Cinelli","year":"2019","journal-title":"J. R. Stat. Soc. Ser. B Methodol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","article-title":"No adjustments are needed for multiple comparisons","volume":"1","author":"Rothman","year":"1990","journal-title":"Epidemiology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1177\/1352458518771875","article-title":"Efficacy of cladribine tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the clarity study","volume":"25","author":"Giovannoni","year":"2019","journal-title":"Mult Scler J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s00415-019-09248-6","article-title":"Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis","volume":"266","author":"Turner","year":"2019","journal-title":"J Neurol."},{"key":"B44","first-page":"631","article-title":"Ublituximab efficacy outcomes in relapsing multiple sclerosis patient subgroups in the ULTIMATE I and II studies","author":"Hartung","year":"2022","journal-title":"Eur J Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s40120-023-00549-7","article-title":"No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: clinician and patient perspectives [narrative review]","volume":"12","author":"Newsome","year":"2023","journal-title":"Neurol Ther."},{"key":"B46","first-page":"22","article-title":"Ofatumumab versus teriflunomide in relapsing multiple sclerosis: analysis of no evidence of disease activity (NEDA-3) from the ASCLEPIOS I and II trials","author":"Hauser","year":"2020","journal-title":"IJMSC."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2055217318760642","DOI":"10.1177\/2055217318760642","article-title":"No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a","volume":"4","author":"Havrdov\u00e1","year":"2018","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B48","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1212\/WNL.98.18_supplement.839","article-title":"et al. Evaluating no evidence of disease activity in patients with relapsing multiple sclerosis: Post Hoc analysis of the phase 3 RADIANCE and open-label extension studies of ozanimod (P7-4012)","volume":"98","author":"Kappos","year":"2022","journal-title":"Neurology."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1177\/13524585241266180","article-title":"Disability patterns in multiple sclerosis: a meta-analysis on RAW and PIRA in the real-world context","volume":"30","author":"Prosperini","year":"2024","journal-title":"Mult Scler J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/1352458519845837","article-title":"Real-world studies provide reliable comparisons of disease modifying therapies in MS\u2013No","volume":"26","author":"Sormani","year":"2020","journal-title":"Mult Scler J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","article-title":"Early aggressive treatment approaches for multiple sclerosis","volume":"23","author":"Simpson","year":"2021","journal-title":"Curr Treat Options Neurol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1177\/13524585241267211","article-title":"Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis","volume":"30","author":"Roos","year":"2024","journal-title":"Mult Scler."},{"key":"B56","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40120-020-00212-5","article-title":"A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis","volume":"9","author":"Giovannoni","year":"2020","journal-title":"Neurol Ther."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011381.pub3","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","author":"Gonzalez-Lorenzo","year":"2024","journal-title":"Cochrane Database Syst Rev."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1177\/1352458516653667","article-title":"Observational data: understanding the real MS world","volume":"22","author":"Kalincik","year":"2016","journal-title":"Mult Scler."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1773074\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:25:34Z","timestamp":1773379534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1773074\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":58,"alternative-id":["10.3389\/fneur.2026.1773074"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1773074","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"article-number":"1773074"}}